Developer docs
API playgroundTry for free, no card

Search company profiles

Ansa Biotechnologies

Full company profile

uuid00005y6

Namestring
Ansa Biotechnologies
Legal namestring
Ansa Biotechnologies, Inc.
Websiteurl
ansabio.com
Company typeenum
Private
Founded yearint
2018
Descriptiontext

Ansa Biotechnologies is a privately held biotechnology company founded in 2018 and headquartered in Emeryville, California, that has developed a proprietary enzymatic DNA synthesis platform for direct synthesis of double-stranded DNA without assembly-based methods. The technology removes constraints associated with traditional chemical synthesis, enabling direct synthesis of complex sequences containing repeats, GC-rich regions, homology arms, regulatory elements, and other features that other vendors reject or modify. Ansa's product portfolio spans three tiers: DNA Fragments (200–900 bp), Clonal DNA (100 bp–7.5 kb), and XL Clonal DNA (7.5–50 kb), with sequence accuracy verified by PacBio HiFi end-to-end sequencing and backed by an industry-first On-Time Guarantee. The company also operates an AI codon language model for sequence optimization and is a member of the International Gene Synthesis Consortium, screening all orders under the NSTC Framework for Nucleic Acid Synthesis Screening.

Ansa sells primarily through a direct e-commerce portal and direct enterprise sales, with a January 2026 strategic collaboration extending distribution through Integrated DNA Technologies (IDT), a Danaher company, for global market access. Customers include gene and cell therapy developers, antibody discovery researchers, contract development and manufacturing organizations (CDMOs), agrigenomics companies, and academic and nonprofit research institutions — including Hexagon Bio, the George Church Lab at Harvard Medical School and MIT, Terrain Bio, the Allen Institute's Seattle Hub for Synthetic Biology, the University of Maryland, and Applied StemCell. Pricing is per-order, quote-based, and varies by sequence complexity, length, and turnaround time, with standard ship times ranging from as few as 4 business days (fragments) to 25 business days (XL clones). Total funding raised exceeds $134 million, including a $68 million Series A led by Northpond Ventures in 2022 and a $54.4 million Series B led by Cerberus Ventures in October 2025.

Short descriptiontext

Ansa Biotechnologies is a private Emeryville, California biotech that offers enzymatic DNA synthesis services producing sequence-perfect DNA fragments, clonal DNA, and XL clonal constructs up to 50 kb for gene therapy, cell therapy, antibody discovery, CDMO, agrigenomics, and academic customers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersEmeryville, United States
HQ citystring
Emeryville
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
enzymatic DNA synthesis, clonal DNA services, synthetic biology tools, gene synthesis platform, DNA fragments manufacturing
Industry4 codes
PRIMARYHLAGAIAF
Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays)
SECONDARYHLAAAIAD
Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAKAE
Plasmid DNA & mRNA Manufacturing Services
SECONDARYHLAAAIAL
Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Synthetic DNA Manufacturing
Social media profiles3 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Custom DNA Synthesis Products
TypeOne Time License
Description

Direct sale of synthetic DNA products including Clonal DNA (up to 7.5 kb), XL Clonal DNA (7.5 kb to 50 kb), and DNA Fragments (200-900 bp). Customers place orders through Ansa's e-commerce portal or via sales engagement. Revenue is generated through per-order pricing based on sequence complexity and length.

ansabio.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales, Supply Chain
Pricing details3 tiers
1DNA Fragment synthesis (200-900 bp) with fast turnaround
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Fragments ship in as few as 4 business days. Minimum mass spec yield 150 ng, average yield 1.5 µg.

ansabio.com
2Clonal DNA synthesis (100 bp - 7.5 kb)
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Clones ship in as little as 11 business days. Includes sequence verification with PacBio HiFi sequencing.

ansabio.com
3XL Clonal DNA synthesis (7.5 kb - 50 kb)
ModelUnit PricingBilling cadencePay-as-you-go
Notes

XL clones ship in as little as 25 business days. Uses pStable-Ind-Chlor-v1.1 single-copy vector with arabinose-inducible copy number.

ansabio.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Ansa Biotechnologies develops and sells custom synthetic DNA manufactured through a proprietary enzymatic DNA synthesis platform. The company directly synthesizes double-stranded DNA up to 50 kb without assembly-based methods, producing DNA Fragments (200-900 bp), Clonal DNA (100 bp to 7.5 kb), and XL Clonal DNA (7.5 kb to 50 kb) that are sequence-verified with PacBio HiFi sequencing and delivered under an industry-first On-Time Guarantee.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Complex repetitive sequences up to 41 kb successfully delivered that other companies declined to synthesize
+3 more records
Product overview1 text field

Ansa Biotechnologies is a biotech company offering enzymatic DNA synthesis services through a unified platform that produces sequence-perfect synthetic DNA. The product portfolio centers on three main tiers: DNA Fragments (200-900 bp) for rapid fragment synthesis, Clonal DNA (100 bp – 7.5 kb) for sequence-verified cloned constructs, and XL Clonal DNA (7.5 kb – 50 kb) for extended-length applications. The platform is distinguished by its ability to directly synthesize complex sequences (high/low GC content, repeats, secondary structures, ITRs) that fail at other vendors, and is backed by an On-Time Guarantee service. Additional offerings include Catalog Vectors and a Custom Vector Early Access Program. Products are ordered through Ansa's e-commerce portal, with distribution also available through Integrated DNA Technologies (IDT) partnership.

Product and service4 records
1DNA Fragments
CategorySynthetic DNA Manufacturing
Description

Direct enzymatic synthesis of double-stranded DNA fragments from 200-900 bp, offering rapid turnaround and the ability to incorporate complex sequence features that challenge traditional chemical synthesis methods.

2Clonal DNA
CategorySynthetic DNA Manufacturing
Description

Direct enzymatic synthesis of double-stranded clonal DNA from 100 bp up to 7.5 kb, featuring sequence-perfect delivery of complex sequences including regulatory elements, homology arms, and repetitive domains that are often rejected elsewhere.

3XL Clonal DNA
CategorySynthetic DNA Manufacturing
Description

Extended-length clonal DNA synthesis service delivering sequence-verified constructs from 7.5 kb to 50 kb, enabling researchers to access full-length genes and large constructs without fragmentation or reassembly.

4Catalog Vectors
CategorySynthetic DNA Manufacturing
Description

Pre-designed cloning, bacterial, mammalian, AAV, and transcription vectors available for ordering alongside Ansa's custom DNA synthesis products.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-08
Description

Ansa co-signed an open letter organized by these organizations urging Congress to mandate screening for synthetic DNA and RNA orders to prevent AI-designed bioweapons. This coalition included AI companies (OpenAI, Anthropic, Google DeepMind, Microsoft AI, Meta, Stripe) and other synthetic biology manufacturers (Twist Bioscience). The initiative calls for legally required screening and record-keeping across the synthetic genetic material industry.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-01-14
Description

Strategic collaboration to expand IDT's synthetic biology portfolio with Ansa's Clonal DNA and XL Clonal DNA products (100 bp to 50 kb). The partnership enables IDT customers to access Ansa's enzymatic DNA synthesis platform for next-generation cell and gene therapy discovery, vaccine research, and agrigenomics applications. Ansa's products are exclusively manufactured in the United States. Jason T. Gammack, CEO of Ansa, stated the collaboration aims to overcome long-standing technical barriers in DNA synthesis, providing researchers with greater access to longer, more complex DNA constructs.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-11
Description

Applied StemCell demonstrated efficient site-specific integration of a 50 kb DNA construct into human induced pluripotent stem cells (iPSCs) using its proprietary TARGATT technology, achieving greater than 20% efficiency at the H11 safe harbor locus. The 50 kb multifunctional construct was produced by Ansa Biotechnologies using enzymatic DNA synthesis and contains multiple expression cassettes enabling immune evasion and tunable gene expression. This milestone enables new applications in allogeneic cell therapy development, multi-protein complex expression, and stable viral vector manufacturing.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Ansa is a member of the International Gene Synthesis Consortium and adheres to their Harmonized Screening Protocol. All requested sequences are screened according to the NSTC Framework For Nucleic Acid Synthesis Screening before being synthesized.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Twist is the leading commercial DNA synthesis provider serving synthetic biology, drug discovery, and academic customers. Ansa competes directly with Twist's gene fragments and clonal gene offerings, while Twist's silicon-based DNA synthesis platform is the dominant incumbent Ansa is attempting to disrupt enzymatically.

TypeEmerging player
Description

Synthego provides synthetic biology tools including synthetic RNA, gene editing reagents, and cell engineering services. There is meaningful overlap in customer base (cell and gene therapy researchers) and product category (synthetic nucleic acids).

TypeEmerging player
Description

Codex DNA (formerly Synthetic Genomics) develops synthetic biology tools, including DNA assembly and protein engineering platforms. It overlaps with Ansa in providing synthetic DNA and engineered biological constructs to biotech and pharma researchers.

TypeBroad incumbent
Description

Agilent provides genomics reagents, oligonucleotide synthesis, and molecular biology tools to a shared biotech and pharma customer base. Agilent is a broad incumbent in the DNA synthesis and molecular biology tools category.

TypeDirect peer
Description

GenScript offers gene synthesis, cloning, and protein services to biotech and pharma customers globally. It is a direct peer in custom gene and clonal DNA synthesis, with broader service portfolio and a much larger installed customer base than Ansa.

TypeBroad incumbent
Description

Eurofins Genomics is a large-scale provider of DNA synthesis, sequencing, and genotyping services globally. It is a broad incumbent addressable by customers with similar use cases (gene synthesis for academic and biotech research) but with a much broader portfolio than Ansa.

TypeEmerging player
Description

Bota Bio operates a synthetic biology platform developing engineered microbes and bioprocesses. It is an emerging player in the broader synthetic biology tooling space, with overlap in customer type (biotech and industrial biotech developers) but with a different product offering (whole-cell engineering vs. DNA synthesis).

8DNA Script
TypeDirect peer
Description

DNA Script is a direct enzymatic DNA synthesis competitor focused on benchtop enzymatic synthesizers and a commercial synthesis service. Both companies share the same novel-method architecture (enzymatic synthesis) and target the same biotechnology customer base.

TypeBroad incumbent
Description

IDT, a Danaher company, is both Ansa's strategic distribution partner and a broad incumbent in oligonucleotides, gene synthesis, and synthetic biology reagents. The two are comparable in customer base (gene therapy, vaccine research, agrigenomics) but IDT operates at significantly greater scale and breadth.

TypeBroad incumbent
Description

Thermo Fisher's GeneArt business offers gene synthesis, genome editing tools, and protein expression services. Ansa's COO previously scaled gene synthesis manufacturing at Thermo Fisher, and the company's offerings directly overlap with GeneArt's gene synthesis portfolio.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors19 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Ansa Biotechnologies

Synthetic DNA Manufacturingansabio.com

Ansa Biotechnologies is a private Emeryville, California biotech that offers enzymatic DNA synthesis services producing sequence-perfect DNA fragments, clonal DNA, and XL clonal constructs up to 50 kb for gene therapy, cell therapy, antibody discovery, CDMO, agrigenomics, and academic customers.

What Ansa Biotechnologies does

Ansa Biotechnologies is a privately held biotechnology company founded in 2018 and headquartered in Emeryville, California, that has developed a proprietary enzymatic DNA synthesis platform for direct synthesis of double-stranded DNA without assembly-based methods. The technology removes constraints associated with traditional chemical synthesis, enabling direct synthesis of complex sequences containing repeats, GC-rich regions, homology arms, regulatory elements, and other features that other vendors reject or modify. Ansa's product portfolio spans three tiers: DNA Fragments (200–900 bp), Clonal DNA (100 bp–7.5 kb), and XL Clonal DNA (7.5–50 kb), with sequence accuracy verified by PacBio HiFi end-to-end sequencing and backed by an industry-first On-Time Guarantee. The company also operates an AI codon language model for sequence optimization and is a member of the International Gene Synthesis Consortium, screening all orders under the NSTC Framework for Nucleic Acid Synthesis Screening.

Ansa sells primarily through a direct e-commerce portal and direct enterprise sales, with a January 2026 strategic collaboration extending distribution through Integrated DNA Technologies (IDT), a Danaher company, for global market access. Customers include gene and cell therapy developers, antibody discovery researchers, contract development and manufacturing organizations (CDMOs), agrigenomics companies, and academic and nonprofit research institutions — including Hexagon Bio, the George Church Lab at Harvard Medical School and MIT, Terrain Bio, the Allen Institute's Seattle Hub for Synthetic Biology, the University of Maryland, and Applied StemCell. Pricing is per-order, quote-based, and varies by sequence complexity, length, and turnaround time, with standard ship times ranging from as few as 4 business days (fragments) to 25 business days (XL clones). Total funding raised exceeds $134 million, including a $68 million Series A led by Northpond Ventures in 2022 and a $54.4 million Series B led by Cerberus Ventures in October 2025.

Ansa Biotechnologies firmographics

Firmographics
Name
Ansa Biotechnologies
Legal name
Ansa Biotechnologies, Inc.
Website
https://ansabio.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
51–100 employees
Short description
Ansa Biotechnologies is a private Emeryville, California biotech that offers enzymatic DNA synthesis services producing sequence-perfect DNA fragments, clonal DNA, and XL clonal constructs up to 50 kb for gene therapy, cell therapy, antibody discovery, CDMO, agrigenomics, and academic customers.
Ownership category
akta.pro rank

Ansa Biotechnologies industry classification

Industry
Product category
Synthetic DNA Manufacturing
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAGAIAF
Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays)
SECONDARYHLAAAIAD
Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAKAE
Plasmid DNA & mRNA Manufacturing Services
SECONDARYHLAAAIAL
Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Enzymatic DNA synthesis
  • Clonal DNA services
  • Synthetic biology tools
  • Gene synthesis platform
  • DNA fragments manufacturing

Where Ansa Biotechnologies is headquartered

Location

Headquarters

HQ city
Emeryville
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Ansa Biotechnologies business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

  1. Custom DNA Synthesis Products: Direct sale of synthetic DNA products including Clonal DNA (up to 7.5 kb), XL Clonal DNA (7.5 kb to 50 kb), and DNA Fragments (200-900 bp). Customers place orders through Ansa's e-commerce portal or via sales engagement. Revenue is generated through per-order pricing based on sequence complexity and length.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goDNA Fragment synthesis (200-900 bp) with fast turnaround
Unit PricingPay-as-you-goClonal DNA synthesis (100 bp - 7.5 kb)
Unit PricingPay-as-you-goXL Clonal DNA synthesis (7.5 kb - 50 kb)

Go-to-market motion2 records

Distribution channels3 records

Marketing channels8 records

Ansa Biotechnologies product offering

Product offering

Core offering

Ansa Biotechnologies develops and sells custom synthetic DNA manufactured through a proprietary enzymatic DNA synthesis platform. The company directly synthesizes double-stranded DNA up to 50 kb without assembly-based methods, producing DNA Fragments (200-900 bp), Clonal DNA (100 bp to 7.5 kb), and XL Clonal DNA (7.5 kb to 50 kb) that are sequence-verified with PacBio HiFi sequencing and delivered under an industry-first On-Time Guarantee.

Product overview

Ansa Biotechnologies is a biotech company offering enzymatic DNA synthesis services through a unified platform that produces sequence-perfect synthetic DNA. The product portfolio centers on three main tiers: DNA Fragments (200-900 bp) for rapid fragment synthesis, Clonal DNA (100 bp – 7.5 kb) for sequence-verified cloned constructs, and XL Clonal DNA (7.5 kb – 50 kb) for extended-length applications. The platform is distinguished by its ability to directly synthesize complex sequences (high/low GC content, repeats, secondary structures, ITRs) that fail at other vendors, and is backed by an On-Time Guarantee service. Additional offerings include Catalog Vectors and a Custom Vector Early Access Program. Products are ordered through Ansa's e-commerce portal, with distribution also available through Integrated DNA Technologies (IDT) partnership.

Differentiator

Problem solved

Functional benefit

Products and services

  • DNA Fragments Direct enzymatic synthesis of double-stranded DNA fragments from 200-900 bp, offering rapid turnaround and the ability to incorporate complex sequence features that challenge traditional chemical synthesis methods.
  • Clonal DNA Direct enzymatic synthesis of double-stranded clonal DNA from 100 bp up to 7.5 kb, featuring sequence-perfect delivery of complex sequences including regulatory elements, homology arms, and repetitive domains that are often rejected elsewhere.
  • XL Clonal DNA Extended-length clonal DNA synthesis service delivering sequence-verified constructs from 7.5 kb to 50 kb, enabling researchers to access full-length genes and large constructs without fragmentation or reassembly.
  • Catalog Vectors Pre-designed cloning, bacterial, mammalian, AAV, and transcription vectors available for ordering alongside Ansa's custom DNA synthesis products.

Quantifiable outcome

  • Complex repetitive sequences up to 41 kb successfully delivered that other companies declined to synthesize
  • +3 more outcomes

Companies that use Ansa Biotechnologies

Customer profile

Named customers6 records

Segments5 records

Ideal customer profiles3 records

Ansa Biotechnologies technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature5 records

Ansa Biotechnologies partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core.

  • Foundation for American Innovation and Institute for ProgresscoreStrategic or Co-development Partner · 8 June 2026Ansa co-signed an open letter organized by these organizations urging Congress to mandate screening for synthetic DNA and RNA orders to prevent AI-designed bioweapons. This coalition included AI companies (OpenAI, Anthropic, Google DeepMind, Microsoft AI, Meta, Stripe) and other synthetic biology manufacturers (Twist Bioscience). The initiative calls for legally required screening and record-keeping across the synthetic genetic material industry.
  • Integrated DNA Technologies (IDT)coreChannel Partner/ Reseller/ Distributor · 14 January 2026Strategic collaboration to expand IDT's synthetic biology portfolio with Ansa's Clonal DNA and XL Clonal DNA products (100 bp to 50 kb). The partnership enables IDT customers to access Ansa's enzymatic DNA synthesis platform for next-generation cell and gene therapy discovery, vaccine research, and agrigenomics applications. Ansa's products are exclusively manufactured in the United States. Jason T. Gammack, CEO of Ansa, stated the collaboration aims to overcome long-standing technical barriers in DNA synthesis, providing researchers with greater access to longer, more complex DNA constructs.
  • Applied StemCellcoreStrategic or Co-development Partner · 11 November 2025Applied StemCell demonstrated efficient site-specific integration of a 50 kb DNA construct into human induced pluripotent stem cells (iPSCs) using its proprietary TARGATT technology, achieving greater than 20% efficiency at the H11 safe harbor locus. The 50 kb multifunctional construct was produced by Ansa Biotechnologies using enzymatic DNA synthesis and contains multiple expression cassettes enabling immune evasion and tunable gene expression. This milestone enables new applications in allogeneic cell therapy development, multi-protein complex expression, and stable viral vector manufacturing.
  • International Gene Synthesis ConsortiumcoreStrategic or Co-development PartnerAnsa is a member of the International Gene Synthesis Consortium and adheres to their Harmonized Screening Protocol. All requested sequences are screened according to the NSTC Framework For Nucleic Acid Synthesis Screening before being synthesized.

Scale indicators5 records

Recent moves9 records

Expansion highlights6 records

Ansa Biotechnologies competitors and assessment

Company assessment

Direct peers

  • Twist Bioscience: Twist is the leading commercial DNA synthesis provider serving synthetic biology, drug discovery, and academic customers. Ansa competes directly with Twist's gene fragments and clonal gene offerings, while Twist's silicon-based DNA synthesis platform is the dominant incumbent Ansa is attempting to disrupt enzymatically.
  • GenScript: GenScript offers gene synthesis, cloning, and protein services to biotech and pharma customers globally. It is a direct peer in custom gene and clonal DNA synthesis, with broader service portfolio and a much larger installed customer base than Ansa.
  • DNA Script: DNA Script is a direct enzymatic DNA synthesis competitor focused on benchtop enzymatic synthesizers and a commercial synthesis service. Both companies share the same novel-method architecture (enzymatic synthesis) and target the same biotechnology customer base.

Emerging players

  • Synthego: Synthego provides synthetic biology tools including synthetic RNA, gene editing reagents, and cell engineering services. There is meaningful overlap in customer base (cell and gene therapy researchers) and product category (synthetic nucleic acids).
  • Codex DNA: Codex DNA (formerly Synthetic Genomics) develops synthetic biology tools, including DNA assembly and protein engineering platforms. It overlaps with Ansa in providing synthetic DNA and engineered biological constructs to biotech and pharma researchers.
  • Bota Bio: Bota Bio operates a synthetic biology platform developing engineered microbes and bioprocesses. It is an emerging player in the broader synthetic biology tooling space, with overlap in customer type (biotech and industrial biotech developers) but with a different product offering (whole-cell engineering vs. DNA synthesis).

Broad incumbents

  • Agilent Technologies: Agilent provides genomics reagents, oligonucleotide synthesis, and molecular biology tools to a shared biotech and pharma customer base. Agilent is a broad incumbent in the DNA synthesis and molecular biology tools category.
  • Eurofins Genomics: Eurofins Genomics is a large-scale provider of DNA synthesis, sequencing, and genotyping services globally. It is a broad incumbent addressable by customers with similar use cases (gene synthesis for academic and biotech research) but with a much broader portfolio than Ansa.
  • Integrated DNA Technologies (IDT): IDT, a Danaher company, is both Ansa's strategic distribution partner and a broad incumbent in oligonucleotides, gene synthesis, and synthetic biology reagents. The two are comparable in customer base (gene therapy, vaccine research, agrigenomics) but IDT operates at significantly greater scale and breadth.
  • Thermo Fisher Scientific (GeneArt): Thermo Fisher's GeneArt business offers gene synthesis, genome editing tools, and protein expression services. Ansa's COO previously scaled gene synthesis manufacturing at Thermo Fisher, and the company's offerings directly overlap with GeneArt's gene synthesis portfolio.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Ansa Biotechnologies social profiles

Digital presence

Ansa Biotechnologies compliance and trust

Trust signal

Compliance2 records

Ansa Biotechnologies financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Ansa Biotechnologies leadership team

Management profile

Number of profiles

Profiles9 records

Ansa Biotechnologies funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors19 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Ansa Biotechnologies M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ansa Biotechnologies

What does Ansa Biotechnologies do?

Ansa Biotechnologies develops and sells custom synthetic DNA manufactured through a proprietary enzymatic DNA synthesis platform. The company directly synthesizes double-stranded DNA up to 50 kb without assembly-based methods, producing DNA Fragments (200-900 bp), Clonal DNA (100 bp to 7.5 kb), and XL Clonal DNA (7.5 kb to 50 kb) that are sequence-verified with PacBio HiFi sequencing and delivered under an industry-first On-Time Guarantee.

Is Ansa Biotechnologies a public or private company?

Ansa Biotechnologies is a private company. It is classified as venture growth investor backed and is currently operating.

When was Ansa Biotechnologies founded?

Ansa Biotechnologies was founded in 2018. It employs 51 to 100 people.

Where is Ansa Biotechnologies based?

Ansa Biotechnologies is headquartered in Emeryville, United States, in the North America region.

How does Ansa Biotechnologies make money?

One revenue line is on record: custom DNA Synthesis Products.

Who are Ansa Biotechnologies's main competitors?

Direct peers on record are Twist Bioscience, GenScript and DNA Script. Emerging players are Synthego, Codex DNA and Bota Bio. Broad incumbents are Agilent Technologies, Eurofins Genomics, Integrated DNA Technologies (IDT) and Thermo Fisher Scientific (GeneArt).

Does Ansa Biotechnologies have an API?

No public API is recorded for Ansa Biotechnologies.

What industry is Ansa Biotechnologies in?

Ansa Biotechnologies's product category is Synthetic DNA Manufacturing. Its primary akta.pro industry code is HLAGAIAF, Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays), with a secondary code of HLAAAIAD, Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
VentureburnAnsa Biotechnologies Raises $71.5M to Expand DNA SynthesisAnsa Biotechnologies raised $71.5 million in an oversubscribed Series C round, led by Blue Water Life Science Advisors, bringing total funding to $211 million. The company will use the funds to expand manufacturing capacity for complex synthetic DNA amid growing demand from AI-enabled biology. New investors and board members joined the round.Startup ResearcherAnsa Biotechnologies Raises $71.5 Million Series C RoundAnsa Biotechnologies raised $71.5 million in an oversubscribed Series C round led by Blue Water Life Science Advisors. The Emeryville, California company produces complex synthetic DNA, and the financing brings total funding to $211 million. The company plans to use the capital to expand capacity and serve more customers.Pulse 2.0Ansa Biotechnologies Raises $71.5 Million To Scale DNA SynthesisAnsa Biotechnologies raised $71.5 million to expand manufacturing capacity and serve more customers. The company quadrupled its capacity last year and now offers enzymatic DNA synthesis up to 50 kilobases. The funding will support longer, more complex sequences and new board members.Dealroom.coAnsa raises $71.5M Series C to scale guaranteed DNA synthesis | Dealroom NewsAnsa Biotechnologies closed a $71.5 million Series C led by Blue Water Life Science, bringing total funding to $211 million. The company uses enzymatic DNA synthesis to produce long, complex synthetic DNA with a delivery guarantee. The funds will scale operations to meet demand from AI-driven drug discovery and biological design.FinancialContent Business PageAnsa Biotechnologies Raises $71.5 Million in Oversubscribed Series C Round to Scale Guaranteed DNA SynthesisAnsa Biotechnologies closed a $71.5 million oversubscribed Series C round, bringing total funding to $211 million. The round includes new investors Illumina Ventures, BEVC, Lightscape Partners, and Agent Capital, and adds Nick Naclerio, Brad Crutchfield, and Nate Cornell to the board. The financing supports scaling its enzymatic DNA synthesis platform amid growing demand for long, complex synthetic DNA.Business & FinancialEnzymatic Deoxyribonucleic Acid (DNA) Synthesis Technology Market Report 2026 Capitalize On 23.5% CAGR: DNA Script, Ansa Biotechnologies And Ribbon Bio Scale Long DNAThe global enzymatic DNA synthesis technology market is projected to grow from $3.05 billion in 2025 to $8.77 billion by 2030, a CAGR of 23.5%. Growth is driven by genomics, personalized medicine, and demand for scalable DNA manufacturing, with partnerships like IDT and Ansa Biotechnologies expanding access.FinancialContent Business PageResearchers Gain Faster Access to Complex DNA as Integrated DNA Technologies and Ansa Biotechnologies Expand Ordering PlatformIDT and Ansa Biotechnologies expanded their partnership to let researchers order complex DNA constructs up to 50 kb through IDT's e-commerce platform. Over 400 institutions across 33 countries have ordered Ansa DNA, with synthesis complexity expanded 42-fold and a 97% fulfillment rate. The companies plan to explore further integration of design, synthesis, and ordering workflows.MorningstarResearchers Gain Faster Access to Complex DNA as Integrated DNA Technologies and Ansa Biotechnologies Expand Ordering PlatformIntegrated DNA Technologies and Ansa Biotechnologies expanded their partnership to let researchers order complex DNA constructs up to 50 kb through IDT's e-commerce platform. Over 400 institutions across 33 countries have ordered Ansa Clonal DNA, with synthesis complexity expanded 42-fold and a 97% fulfillment rate. The companies plan to explore further integration of design, synthesis, and ordering workflows.EIN PresswireAxio BioPharma Selects Ansa Biotechnologies as Preferred Gene Synthesis ProviderAxio BioPharma named Ansa Biotechnologies as its preferred gene synthesis provider, routing gene synthesis for its high-throughput antibody lab, Axio Forge. Ansa's platform offers a 3-5 week turnaround and an on-time guarantee, aiming to reduce schedule risk in antibody production workflows.FortuneSam Altman, Dario Amodei urge Congress to guard against AI-enabled bioweaponsThe CEOs of OpenAI, Anthropic, and Microsoft AI have co-signed an open letter to Congress urging mandatory federal screening for companies selling synthetic DNA and RNA materials that could be weaponized using AI. The letter, organized by the Foundation for American Innovation and the Institute for Progress, was also signed by synthetic biology companies Twist Bioscience and Ansa Biotechnologies, along with dozens of life sciences and national security experts. The initiative calls for legally required screening and record-keeping across the synthetic genetic material industry amid concerns that advancing AI models are lowering barriers for bad actors to develop biological weapons.